Management in Medistim ASA purchases shares

Medistim ASA (MEDI) · publisert 16. november 2021 kl. 08:00 · vis på NewsWeb

Transaksjoner

Person	Rolle	Type	Volum	Pris	Dato	ISIN	Handelsplass	Tolket via
Hæge Wetterhus	VP marketing	acquisition	663	301,7 NOK	15. november 2023	–	–	llm
Anne Waaler	VP Medical	acquisition	1 989	301,7 NOK	15. november 2023	–	–	llm
Roger Morberg	VP sales	acquisition	1 989	301,7 NOK	15. november 2023	–	–	llm
Erik Swensen	VP development	acquisition	994	301,7 NOK	15. november 2023	–	–	llm
Tone Veiteberg	VP QA\Reg	acquisition	1 989	301,7 NOK	15. november 2023	–	–	llm
Medistim Norge AS	CEO	acquisition	1 326	301,7 NOK	15. november 2023	–	–	llm
Håkon Grøthe	VP Innovation	acquisition	1 989	301,7 NOK	15. november 2023	–	–	llm
Mike Farbelow	President in Medistim USA Inc	acquisition	1 989	301,7 NOK	15. november 2023	–	–	llm
Thomas Jakobsen	CFO	acquisition	2 652	301,7 NOK	15. november 2023	–	–	llm
Medistim ASA	–	disposal	15 578	301,7 NOK	15. november 2023	–	–	llm

Meldingstekst

Management in Medistim ASA has the 15th of November purchased shares form Medistim ASA. This is part of the company long term incentive plan approved by the general meeting the 27th of April. Price per share was NOK 301,7. The following members of management has purchased shares: VP marketing Hæge Wetterhus purchased 663 and has 663 shares after the purchase. VP Medical Anne Waaler purchased 1989 shares and has 2.440 shares after the purchase. VP sales Roger Morberg purchased 1989 shares and has 10427 shares after the purchase. VP development Erik Swensen purchased 994 shares and has 10994 shares after the purchase. VP QA\Reg Tone Veiteberg purchased 1989 shares and has 1989 shares after the purchase. CEO in Medistim Norge AS purchased 1326 shares and has 1326 shares after the purchase. VP Innovation Håkon Grøthe purchased 1989 shares and has 1989 shares after the purchase. President in Medistim USA Inc, Mike Farbelow, purchased 1989 shares and has 1989 shares after the purchase. CFO Thomas Jakobsen purchased 2652 shares and has 22748 shares after the purchase. Medistim ASA has sold 15578 shares and has 108422 owns shares after the sale.